Logo

Prestige Signs an Exclusive Agreement with Teva to Commercialize Tuznue (biosimilar- trastuzumab) in Israel

Share this
Prestige Signs an Exclusive Agreement with Teva to Commercialize Tuznue (biosimilar- trastuzumab) in Israel

Prestige Signs an Exclusive Agreement with Teva to Commercialize Tuznue (biosimilar- trastuzumab) in Israel

Shots:

  • Teva to get an exclusive right to commercialize Tuznu in Israel- leveraging its marketing capabilities and experience in bringing pharmaceutical products to market and will be responsible for local registration- sales- and marketing in Israel
  • Prestige will assume responsibility for product registration with the EMA and commercial supply of Tuznue from its manufacturing facilities in Osong- Korea
  • Tuznue is biosimilar referencing Roche’s Herceptin (trastuzumab)- used to treat HER2-overexpressing BC & m-gastric adenocarcinoma. Additionally- the EMA has accepted an MAA for Tuznue based on the global clinical trial results

 ­ Ref: BusinessWire | Image: BioSpectrum Asia

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions